MGFA has partnered with Bionews to feature the Myasthenia Gravis News feed on our website, providing the community with research updates, disease management insights, and relevant news. All content is original and produced by Bionews’ editorial staff, and perspectives from patients and caregivers. Information is not meant to replace or provide medical advice.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- I didn’t achieve my running goal, but training taught me something valuable
by Sarah Bendiff on June 11, 2026 at 2:00 pmFor years, I had a big goal: to run a race, a trail, or maybe even a marathon someday. It wasn’t because I particularly love running, but because I wanted to prove to myself that, even though I live with myasthenia gravis (MG), with the right training, I could be just as capable as a The post I didn’t achieve my running goal, but training taught me something valuable appeared first on Myasthenia Gravis News.
- Imaavy now approved in UK as treatment option for generalized MG
by Margarida Maia, PhD on June 11, 2026 at 1:00 pmThe infusion therapy Imaavy (nipocalimab) is now approved in the U.K. for treating people ages 12 and older with generalized myasthenia gravis (MG). The new authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA), the body that regulates the use of medications in Great Britain, allows the Johnson & Johnson therapy to be used for The post Imaavy now approved in UK as treatment option for generalized MG appeared first on Myasthenia Gravis News.
- Guest Voice: Finally receiving an MG diagnosis helps me understand life
by Antonella Mifsud on June 10, 2026 at 2:00 pmEverything began when I was 12 years old, still in school, and suddenly started seeing double. I didn’t understand what was happening, and it scared me. After school, I told my parents, who immediately took me to our general practitioner (GP) and arranged a visit with an optometrist. Both the doctor and the optometrist found The post Guest Voice: Finally receiving an MG diagnosis helps me understand life appeared first on Myasthenia Gravis News.
- Low-dose trazodone found in study to safely ease insomnia in mild MG
by Patricia Inacio, PhD on June 10, 2026 at 12:30 pmFor most people with mild, stable myasthenia gravis (MG), taking a low dose of trazodone hydrochloride, an oral antidepressant also commonly used as a sleep aid, can help ease insomnia —difficulty falling asleep, staying asleep, or waking up too early — without worsening MG symptoms or causing breathing problems. That’s according to a small, retrospective The post Low-dose trazodone found in study to safely ease insomnia in mild MG appeared first on Myasthenia Gravis News.
- Eliminate ‘wait and see’ from your MG toolkit
by Bionews Staff on June 10, 2026 at 11:00 amNizar Souayah, MD, explains how a “wait and see” approach in MG can allow silent disease progression and delay needed care. The post Eliminate ‘wait and see’ from your MG toolkit appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.